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Abstract
Introduction: Psoriasis is a chronic immune-inflammatory-mediated disease affecting approximately 1-3% of the population worldwide. All 
around the world, there is growing evidence of the association between psoriasis and comorbidities, especially metabolic syndrome which 
increases the risk of cardiovascular disease. Co-morbidities are likely linked to underlying chronic inflammatory nature of psoriasis.
Aim: The objectives of our study were to determine the prevalence of diabetes, lipid abnormalities, and cardiovascular risk factors in patients 
with plaque psoriasis, and also to investigate metabolic syndrome associated with plaque psoriasis.
Material and Methods: One hundred and twenty patients with psoriasis vulgaris diagnosed clinically and histopathologically were recruited. 
A detailed history and examination was recorded for all study subjects, including the age and gender of the patients, extent of psoriasis, 
duration, and age at onset. Metabolic syndrome was diagnosed in the presence of three or more criteria of abdominal obesity, blood pressure 
>130/85 mmHg, fasting blood glucose ≥100 mg/dl, hypertriglyceridemia >150 mg/dl, and low HDL cholesterol (<40 mg/dl for males, <50mg/
dl for females). 
Results: Prevalence of various comorbidities was: central obesity (58.3%), hypertension (46.79%), dyslipidaemia (43.3%), diabetes mellitus 
(26.7%), metabolic syndrome (25%), ischaemic heart disease (5%) and stroke (2.4%). Prevalence of metabolic syndrome was more in patients 
who had longer mean disease duration of psoriasis.
Conclusions: The perception of psoriasis being merely ‘skin deep’ has to change among clinicians. Active screening for these cardiovascular 
comorbidities in all psoriasis patients is highly recommended.
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Introduction
Psoriasis  is  a  chronic  immune-inflammatory-mediated 
disease affecting approximately 1-3% of the general population 
[1,2]. Psoriasis is not just a disease of skin and joints, but is a 
systemic disease that is connected with a range of comorbidities- 
especially metabolic syndrome and cardiovascular disease. Co-
morbid  conditions  linked  with  psoriasis  are  associated  with 
increasing  rates  of  morbidity  and  mortality  [3].  Metabolic 
syndrome  is  a  cluster  of  risk  factors  including  central 
obesity, atherogenic dyslipidaemia, hypertension and glucose 
intolerance. It is a strong predictor of cardiovascular diseases, 
diabetes  and  stroke  [4].  Similarities  exist  among  psoriasis, 
metabolic  syndrome  and  atherosclerosis,  with  all  three 
conditions  characterized  by  an  inflammatory  process  driven 
by  Th1  cytokines  [5,6].  Increasing  population-based  studies 
have suggested a relationship between psoriasis and metabolic 
syndrome  [7].  Purpose  of  our  study  was  to  determine  the 
prevalence of comorbidities in patients with psoriasis vulgaris, 
with special emphasis on metabolic syndrome, as it remains 
largely unelucidated in the Indian population. 
Material and Methods
Prospective,  observational  hospital  based  study.  One 
hundred and twenty patients with psoriasis vulgaris diagnosed 
clinically and histopathologically were included in this study 
which was carried out of our Department of Dermatology from 
March 2011 to August 2012 for a period of 18 months. Patients 
with plaque-type psoriasis aged above 18 years were included 
in  the  study.  Patients  receiving  systemic  treatment  for  their 
psoriasis in the last one month were excluded. Informed consent 
was taken from patients who were enrolled. Information sheets 
for  the  patients  included  age,  gender,  weight,  height,  body 
mass index (BMI), waist circumference, smoking habits, blood 
pressure, age of onset, and duration of the disease.
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area (%BSA) and psoriasis area severity index (PASI). BSA 
is calculated using the “rule of nines”. BSA is the arithmetic 
mean of the affected skin surface based on the assumption that 
the  head  (H)  presents  10%,  the  upper  extremities  (U)  20%, 
the trunk (T) 30%, and the lower extremities (L) 40% of the 
total body surface [8]. PASI is a composite score from 0 to 
72. PASI assesses the degree of erythema (E), inﬁltration (I), 
and desquamation (D) in the above-mentioned sites (H, U, T, 
L) [9]. These features are appraised in these sites using a four-
point scale: 0: no symptoms; 1: slight symptoms; 2: moderate 
symptoms; 3: marked symptoms; 4: very marked symptoms. 
The scores used to describe the coverage of skin disease in the 
distinct areas are: 0: 0%; 1: < 10%; 2: 10–29%; 3: 30–49%; 4: 
50–69%; 5: 70–89%; 6: 90–100%. Therefore, PASI takes both 
coverage (A) and severity (E, I and D) into consideration. It is 
calculated by:
PASI = 0.1 * (EH + IH + DH) AH + 0.2 * (EU + IU + DU) AU+ 
0.3 * (ET + IT + DT) AT + 0.4 * (EL + IL + DL) AL
It was classiﬁed as moderate to severe in patients with PASI > 
10, and mild in patients with PASI ≤ 10. BMI was calculated 
as weight/height (kg/m2). Metabolic syndrome was diagnosed 
using the South Asian Modiﬁed National Cholesterol Education 
Program Adult Treatment Panel III criteria (SAM-NCEP criteria) 
[10]. If three or more of the following were present, the patient 
was  diagnosed  as  having  metabolic  syndrome:  abdominal 
obesity  (deﬁnition  of  abdominal  obesity  was  modiﬁed  using 
Asia Paciﬁc WHO guidelines as waist circumference ≥90cm for 
males and ≥80cm for females), blood pressure >130/85 mmHg, 
fasting blood glucose ≥100 mg/dl, hypertriglyceridemia >150 
mg/dl, or low HDL cholesterol (<40 mg/dl for males and <50 
mg/dl for females). ECG was done in all patients and angiogram 
wherever  required.  Statistical  comparisons  were  performed 
using the Student’s t- test. The data were considered statistically 
signiﬁcant if p values were less than 0.05 (p<0.05).
Results
The study  group  included 120  patients, with 86 (71.7%) 
males and 34 (28.3%) females with a male to female ratio of 
2.53:1. Age of the patients ranged from 18 years to 62 years 
with a mean age of 37.34 years. Duration of the disease ranged 
from 2 months to 30 years, with a mean duration of 6.67 years. 
Mean age at onset was 31.41 years, with minimum age 12 years 
and maximum age 60 years at onset. Severity of psoriasis was 
moderate to severe in 68 (56.7%) of the patients and mild in 
52 (43.3%) of the patients with a Median PASI of 13.05. PASI 
score ranged from 5 to 70.  BSA involved ranged from 6% to 
80%, with a Median BSA of 20%. 
Central obesity was the most prevalent comorbidity, affecting 
70 (58.3%) patients with psoriasis, followed by hypertension, 
dyslipidaemia, diabetes mellitus, metabolic syndrome, ischaemic 
heart disease and stroke (Tabl. I). Waist circumference ≥90cm in 
men and ≥ 80cm in women was observed in 42 (35%) and 28 
(23.3%) patients respectively. Obesity measured by BMI was 
present in 64 (53.3%) patients. Metabolic syndrome was seen 
in 30 (25%) patients of psoriasis. Distribution of risk factors 
and different components of Metabolic Syndrome are given in 
Table II. 
On  analyzing  psoriatic  patients  with  and  without  metabolic 
syndrome, we found that patients with metabolic syndrome had 
longer  mean  disease  duration  than  psoriatic  patients  without 
metabolic  syndrome,  which  was  signiﬁcant.  There  was  no 
signiﬁcant  difference  regarding  psoriasis  severity,  gender  or 
prevalance  of  smoking  between  psoriatic  patients  with  and 
without metabolic syndrome (Tabl III). Metabolic syndrome in 
psoriasis was seen more commonly in the patients aged above 
sixty years, however we also observed early onset of metabolic 
syndrome in psoriasis (Tabl. IV).
Discussion
Recent studies on western population show that psoriasis is 
associated with metabolic disorders such as hypertension, type 
II diabetes mellitus, dyslipidemia, abdominal obesity, insulin 
resistance,  and  cardiac  disorders  and  the  risk  of  metabolic 
syndrome is increased in patients with psoriasis [11-19]. Meta-
analysis of studies has shown that psoriatics had increased odds 
(two-fold) of developing metabolic syndrome compared with 
the general population. 
Metabolic syndrome has a high prevalence among psoriasis. 
Possible  biologic  mechanisms  for  this  may  be  due  to: 
chronically elevated free fatty acid (FFA) levels which lead to 
adipocyte dysfunction which in turn inhibit insulin secretion and 
up-regulation of proinflammatory adipokines like adiponectin, 
leptin, resistin and visfatin [7]. 
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Comorbidities  Number (%)
Central obesity  70 (58.3%)
Hypertension  56 (46.7%)
Dyslipidemia  52 (43.3%)
Diabetes Mellitus 32 (26.7%)
Metabolic Syndrome 30 (25%)
Ischaemic Heart Disease (IHD) 6 (5%)
Stroke 3 (2.4%)
Table I. Prevalence of different comorbidities in psoriasis.
Risk factors/Components of 
Metabolic Syndrome 
Number (%) 
Smokers  18 (15%) 
Alcoholic  46 (38.3%) 
Waist circumference:
Male                                                              
Female 
                                                                              
42 (35%)                                                                      
2 8   ( 2 3 . 3 % )                                                                                                                                           
        
Hypertension  56 (46.7%) 
Hypertriglyceridemia 52 (43.3%) 
Low Level HDL  40 (33.3%) 
Diabetes Mellitus (FBS>100mg/dl)  32 (26.7%) 
Table II. Distribution of risk factors and components of 
Metabolic Syndrome.16   © Our Dermatol Online 1.2014
Studies on the Indian population with relation to psoriasis and 
its  comorbidities  and  metabolic  syndrome  are  limited.  The 
prevalence of metabolic syndrome in psoriasis was 25% in our 
study, which is consistent with other Indian studies, which have 
shown a prevalence ranging from 18.2% - 44.1% [4,20-23].   
This wide variation in the prevalence of metabolic syndrome 
could be due to ethnic, dietary and lifestyle changes in different 
parts of the country. Prevalence of different metabolic syndrome 
components in our study is compared with other Indian studies 
in Table V. Association with smoking was seen in 15% of our 
patients which is consistent with a study by Madanagobalane et 
al [20]. Association with smoking may be partly explained by 
the action of nicotine in promoting Th1 mediated inflammation 
[6]. Smoking induces an overproduction of IL-1β, TNF-α and 
TGF-β,  which  have  been  associated  with  psoriasis  severity 
[24]. In our study 38.3% of patients were alcoholic, other Indian 
studies have reported an association of 9.1% to 17.7% [20,23].  
Alcoholism  has  been  related  with  psoriasis,  and  studies 
have reported 1.3–1.6 fold increased risk in development of 
psoriasis  in  alcoholics  [25].  Hypertriglyceridemia  and  low 
HDL  levels  were  seen  in  43.3%  and  33.3%  of  our  patients 
which is consistent with a study by Madanagobalane et al [20]. 
Pro-inflammatory  cytokines TNF-α  and  IL-6  over  expressed 
in  psoriasis  contributes  to  dyslipidaemia  [26].  Obesity  was 
observed in 58.3% of our patients which is much higher than 
other  Indian  studies  which  have  reported  an  association  of 
14.6% to 38% [21,22].
Leptin produced by adipose tissue and increased TNF-α acts 
as  a  potential  link  between  obesity  and  psoriasis  [27,28]. 
Diabetes mellitus was seen in 26.7% of our patients, while other 
Indian studies have reported a prevalence ranging from 16% to 
61% [20,22]. Chronically elevated FFA levels inhibit insulin 
secretion, and TNF-α and IL-6 contributes to insulin resistance 
[7,26]. Fifty six (46.7%) patients were hypertensive in our study 
which is consistent with another Indian study by Nisa et al.[21]. 
Henselar et al in 40,000 dermatological patients found 1.9 fold 
greater  likelihood  of  hypertension  in  psoriatics  compared  to 
other dermatological conditions [11]. 
Our study showed a signiﬁcant relationship between duration 
of psoriasis and metabolic syndrome, which is consistent with a 
study by Nisa et al.[21]. 
There was no signiﬁcant relationship between psoriasis severity 
and metabolic syndrome in our study, which is consistent with 
other Indian studies [20,21]. 
Characteristic  With MS (n=30)  Without MS (n=90)  t-test 
Sex (M / F)  21 / 9  65 / 25  NS 
Disease duration  13.67 ± 11.87  6.46 ± 5.80  (P<0.0005) 
Smoker  6  12  NS 
PASI >10  21  47  NS 
BSA >10%  23  55  NS 
Mean PASI  14.30 ± 12.37  16.77 ± 14.53  NS 
Mean BSA  25.80 ± 21.17  27.55 ± 25.7  NS 
Table III. Descriptive features of psoriatic patients with and without Metabolic Syndrome (MS).
NS=Not significant
Comorbidities (%)  Nisa et al Khunger et al  Madanagobalane et al  Present  study
Smoking  42%  -  16.1%  15%
Hypertriglyeridemia  48.6%  16%  33.9% 43.3% 
Hypertension  49.3%  26%  30.5% 46.7% 
Low HDL levels  56.6%  -  36.4% 33.3% 
Obesity  14.6%  38%  34.7% 58.3% 
Diabetes Mellitus  18%  16%  61% 26.7% 
Table IV. Comparision of prevalence of metabolic syndrome components in different Indian studies.
Age Group  %
18-30 Yrs 12.9%
31-40 Yrs 29.7%
41-50 Yrs 44.4%
51-60 Yrs 37.5%
>60 Yrs 50%
Table V. Prevalance of Metabolic Syndrome among 
different age groups.However,  Langan  et  al  found  a  robust  dose-response 
relationship  between  psoriasis  severity  and  prevalence  of 
metabolic syndrome [29]. This observation was supported by 
the translational data that T- helper inflammatory cytokines are 
increased in skin and sera of psoriatic patients and these exert 
systemic effects on insulin regulation and lipid metabolism [30]. 
Onset of metabolic syndrome in psoriasis was seen at a younger 
age in our study which is consistent with a study reported by 
Nisa  et  al.[21].  Relative  risk  of  cardiovascular  mortality  is 
highest in younger patients less than forty years, with severe 
psoriasis [15]. So early therapeutic intervention would diminish 
the risk of cardiovascular disease and mortality in psoriasis.
Our  results  showed  that  psoriasis  predisposes  to  the 
development  of  a  distinct  cluster  of  concomitant  diseases, 
including  hypertension,  dyslipidemia,  obesity  and  metabolic 
syndrome. Hence all patients with psoriasis should be monitored 
for associated co-morbid conditions. For effective management 
of psoriasis and related co-morbidities, an integrated approach 
targeting both cutaneous and systemic manifestations may be 
beneﬁcial.
Limitation of this study was that the sample size was not large 
enough  to  represent  the  general  population.  Further  large 
prospective, randomized, controlled, population-based studies 
should be undertaken to conﬁrm the association and causality 
between psoriasis and metabolic syndrome.  
Conclusion
Approach  psoriasis  as  a  potentially  multisystem  disorder 
and alert patients to the potentially negative effects of psoriasis 
as it relates to other aspects of their health.
Can  we  now  consider  psoriasis  as  a  cutaneous  marker  for 
metabolic syndrome?
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